Flinders Island Cup – Race for a Cure 2022

NeuroEndocrine Cancer Australia were delighted with the outcome of in inaugural Flinders Island Cup – Race for a Cure.

NET Patient Rob Hammond created this first ever race day in support of NECA, working closely with Neil Walsh and Peter Staples (Tas Racing) to ensure not only vital funds were raised, but much needed awareness right across Tasmania.

WinTV (Ch9) and Channel 7 interviewed Rob Hammond, NECA CEO Meredith Cummins, NET Patient Caitlin Bailey and her Nan Kaye, NET Carer and CAG Member Philippa Morgan. Click the videos below to see the coverage. Many thanks to Peter Staples for facilitating an article in Mercury Newspaper which ran editorial on October 26th.

We were joined by other NET Patients during the evening where we dined having full view of the Mowbray Racetrack below – Launceston really put on the weather with a balmy evening ending in a beautiful spring rain.

Brent Crawford emceed the evening and Hayden auctioned off very special prizing, including shares in a racehorse and a trip to Flinders Island. We are very pleased to say that over $47,646 has been raised!

Many thanks to everyone involved, particularly the entire Hammond family whose generosity of time and spirit has delivered awareness, funds and a sense of community to the Tasmanian NET patients.


Win News still

Mercury Newspaper October 26
Examiner Race for a Cure
Race For Cure

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

Expressions of interest open for ANZSNM nurse and allied health workshop in Canberra

Over 1,000 Nurses Now Enrolled in NECA’s Free Education Modules

NECA partners with Oncidium ahead of World Radiotheranostics Day 2026

ACCN Hosts Inaugural Regional, Rural and Remote Cancer Care Workshop in Dubbo

Walk, run, or ride this March4NETs!

For its third year, March4NETs will run throughout March 2026.

Get involved and support the 31,000 Australians living with neuroendocrine cancer.